Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (1-10 of 212) with videos related to

Pageof 22
Sort By:
Future Oncology (London, England)|April 24, 2014
36th San Antonio Breast Cancer Symposium: focus on clinical trial resultsWilliam Jacot
Annals of Translational Medicine|November 16, 2023
The quest for the optimal biomarker: is extending the spectrum of targeted <i>PIK3CA</i> mutations in breast cancer carcinoma worthwhile?Stanislas Quesada, William Jacot
La Revue Du Praticien|June 8, 2023
[Therapeutic advances in HER2+ breast cancer]Marie Alexandre, William Jacot
The Lancet. Oncology|April 11, 2022
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancerStanislas Quesada, William Jacot
The Oncologist|July 24, 2012
TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?Pierre-Jean Lamy, William Jacot
Diagnostic Pathology|February 2, 2012
Worldwide variations in EGFR somatic mutations: a challenge for personalized medicinePierre-Jean Lamy, William Jacot
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Antisense oligonucleotides in lung cancerJean-Louis Pujol, William Jacot
Expert Opinion on Pharmacotherapy|February 24, 2021
Alpelisib for the treatment of <i>PIK3CA</i>-mutated, hormone receptor-positive, HER2-negative metastatic breast cancerFanny Leenhardt, Marie Alexandre, William Jacot
Cancers|April 17, 2020
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic ReviewIléana Corbeau, William Jacot, Séverine Guiu
Clinical Lung Cancer|February 8, 2005
Biologic staging of non-small-cell lung cancer: prospect or proposal?Fabrice Barlesi, William Jacot, Jean-Louis Pujol
Pageof 22

Showing results (1-10 of 212) with videos related to

Sort By:
Pageof 22
Future Oncology (London, England)|April 24, 2014
36th San Antonio Breast Cancer Symposium: focus on clinical trial resultsWilliam Jacot
Annals of Translational Medicine|November 16, 2023
The quest for the optimal biomarker: is extending the spectrum of targeted <i>PIK3CA</i> mutations in breast cancer carcinoma worthwhile?Stanislas Quesada, William Jacot
La Revue Du Praticien|June 8, 2023
[Therapeutic advances in HER2+ breast cancer]Marie Alexandre, William Jacot
The Lancet. Oncology|April 11, 2022
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancerStanislas Quesada, William Jacot
The Oncologist|July 24, 2012
TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?Pierre-Jean Lamy, William Jacot
Diagnostic Pathology|February 2, 2012
Worldwide variations in EGFR somatic mutations: a challenge for personalized medicinePierre-Jean Lamy, William Jacot
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Antisense oligonucleotides in lung cancerJean-Louis Pujol, William Jacot
Expert Opinion on Pharmacotherapy|February 24, 2021
Alpelisib for the treatment of <i>PIK3CA</i>-mutated, hormone receptor-positive, HER2-negative metastatic breast cancerFanny Leenhardt, Marie Alexandre, William Jacot
Cancers|April 17, 2020
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic ReviewIléana Corbeau, William Jacot, Séverine Guiu
Clinical Lung Cancer|February 8, 2005
Biologic staging of non-small-cell lung cancer: prospect or proposal?Fabrice Barlesi, William Jacot, Jean-Louis Pujol
Pageof 22